Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency

Video

Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.